...That changed in March when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd....

...in multiple Phase II trials to treat solid tumors. Yanyuan Capital leads Asieris’ series C Asieris...
...accuracy of those statements during the COVID-19 crisis. Targets MetAP2 - Methionine aminopeptidase 2 BioCentury Staff APL-1202 Apexigen Inc. Asieris...

...January. Asieris said the over-booked round should fund operations for about 18 months. This year, Asieris...
...an ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end. Asieris...
...the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Asieris Pharmaceuticals Co. Ltd., Taizhou, China Jennie Walters APL-1202 Asieris...

...month. Asieris said the over-booked round should fund operations for about 18 months. In 2018, Asieris...
...ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end 2018. Asieris...
...exclusive rights to the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Jennie Walters APL-1202 Asieris...